Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Orquest Healos

This article was originally published in The Gray Sheet

Executive Summary

Bone graft substitute is as safe and effective as an autograft in spinal fusion procedures, according to results of a randomized, 29-patient, two-center European study. The findings, presented at Eurospine 1999 on Sept. 11, show that 10 of 13 Healos patients and 13 of 16 autograft patients were considered successfully treated at 12 months. Use of a substitute for autograft in spinal fusions is expected to avoid difficulties related to the harvesting procedure - including an increase in surgery time, longer hospital stays and post-operative disability. U.S. clinical trials of Healos are under way
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT012297

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel